Horm Metab Res 2011; 43(1): 55-61
DOI: 10.1055/s-0030-1268006
Humans, Clinical

© Georg Thieme Verlag KG Stuttgart · New York

Inhibition of Growth Hormone Receptor Activation by Pegvisomant may Increase Bone Density in Acromegaly

C. Jimenez1 , M. Ayala-Ramirez1 , J. Liu2 , R. Nunez3 , R. F. Gagel1
  • 1Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
  • 2Department of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
  • 3Department of Nuclear Medicine, The M.D. Anderson Cancer Center, Madrid, Spain
Further Information

Publication History

received 05.06.2010

accepted 20.10.2010

Publication Date:
22 November 2010 (eFirst)

Abstract

Treatment of acromegaly with pegvisomant lowers serum IGF-1 and raises serum growth hormone. As both IGF-1 and GH are important for bone growth and remodeling, we were concerned that lowering of IGF-1 could cause loss of bone. To evaluate the effects of treatment of acromegaly with pegvisomant on bone mineral density (BMD) we developed an observational, prospective study. 7 acromegaly patients participated in the study. Male and female subjects aged 18 years or more were eligible to participate. Patients were eugonadal or on adequate gonadal replacement therapy for at least 3 years before participating in the study. These patients were treated with a mean dosage of 20 mg of pegvisomant daily for up to 7 years. Bone mineral density (BMD) was evaluated by dual X-ray absorbtiometry (DXA) at baseline, 8, and 18 months as a part of a prospective trial and periodically thereafter. Baseline mean serum insulin-like growth factor-1 (IGF-1) concentration±SD was elevated in all patients (679.86±138.21 ng/ml). The IGF-1 concentrations at 18 months decreased significantly from baseline (p=0.016). Wilcoxon signed-rank tests showed significant increases in the spine BMD from baseline to 18 months (p=0.016) and significant increases in the right hip BMD from baseline to 18 months (p=0.032). The range of the increases was 4.3–17.8% at 7 years. It is concluded that successful treatment of acromegaly with pegvisomant increases BMD.

References

Correspondence

Asst. Prof. Camilo Jimenez
MD, Prof. Robert F. Gagel, MD 

Department of Endocrine Neoplasia

and Hormonal Disorders

Unit 1461

The University of Texas M. D.

Anderson Cancer Center

1400 Pressler Street

Houston 77030

Texas

USA

Phone: +1/713/792 2841

Fax: +1/713/794 4065

Email: cjimenez@mdanderson.org

Email: rgagel@mdanderson.org